Lorlatinib in Tyrosine Kinase Inhibitor−Naive Advanced -Positive Non−Small Cell Lung Cancer

What is the efficacy and safety of lorlatinib in -positive non−small cell lung cancer (NSCLC)?This nonrandomized clinical trial of 32 patients found that lorlatinib demonstrated a 73% objective response rate, median progression-free survival of 53.6 months, and overall survival not reached. In patients who were tyrosine kinase inhibitor (TKI)−naive compared with previously treated, objective response rate was 90% vs 60%, and median progression-free survival was not reached vs 35.8 months; grade 3 and 4 adverse effects included hypertriglyceridemia (16%) and hypercholesterolemia (25%), but no treatment-related deaths.Lorlatinib demonstrated durable efficacy and safety in TKI-naive advanced -positive NSCLC, supporting its potential use in earlier lines of therapy.

Corresponding Author: Ji-Youn Han, MD, PhD, Center for Lung Cancer, Division of Hematology and Oncology, Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsan-dong-gu, Goyang, Republic of Korea (jymama@ncc.re.kr).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.